Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells
Open Access
- 16 February 2006
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 13 (11), 926-931
- https://doi.org/10.1038/sj.gt.3302738
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Metabolic Biotinylation Provides a Unique Platform for the Purification and Targeting of Multiple AAV Vector SerotypesMolecular Therapy, 2006
- Altering AAV tropism with mosaic viral capsidsMolecular Therapy, 2005
- Efficient Transduction of Vascular Endothelial Cells with Recombinant Adeno-Associated Virus Serotype 1 and 5 VectorsHuman Gene Therapy, 2005
- Cross-Dressing the Virion: the Transcapsidation of Adeno-Associated Virus Serotypes Functionally Defines SubgroupsJournal of Virology, 2004
- Cell-Type-Specific Characteristics Modulate the Transduction Efficiency of Adeno-Associated Virus Type 2 and Restrain Infection of Endothelial CellsJournal of Virology, 2002
- Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad SpecificityJournal of Virology, 2002
- Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface ReceptorsHuman Gene Therapy, 2001
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type VirusesHuman Gene Therapy, 1999
- Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in BrainHuman Gene Therapy, 1998